Should We Start Thinking Again About Bioresorbable Stents?

Coronary revascularization with drug-eluting stents (DES) is very frequent, especially in acute coronary syndromes, but these metallic stents are permanent foreign bodies that activate the entire inflammatory system.

¿Deberíamos comenzar a pensar nuevamente en los stents bioabsorbibles?

Using bioresorbable stents (BRS) emerged as an alternative to this challenge. Although the initial results of the ABSORB study were not as expected (probably due to a lack of technological development), a new stage in the development of these devices could begin with the new second-generation MAGMARIS stent.

Researchers conducted a single-center analysis of bioresorbable stents implanted from 2012 to 2020 in patients with acute coronary syndromes, following the evolution of the MAGMARIS (MAG) stent in 193 patients and the ABSORB (ABS) stent in 160 patients.

The primary endpoint (PEP) was a safety composite that included all-cause mortality, infarction, and definite or probable thrombosis at 30 days and 1 year. 

The mean age was 65 years, 37% of patients had diabetes, 85% experienced hypertension, 4% suffered from atrial fibrillation, and 38% had a prior angioplasty. Patients who received MAG had higher rates of unstable angina and non-ST-segment-elevation acute myocardial infarction. Similarly, they presented a higher ejection fraction (60% vs. 55%; p < 0.001).

Read also: A Nod to Catheter-Guided Thrombolysis in Pulmonary Thromboembolism.

In all cases, correct pre-dilatation and preparation of the lesion for stent implantation was performed. The most frequently treated artery was the anterior descending (AD): it received 1.2 stents/patient and double antiplatelet therapy.

At 30 days and at 1 year, the PEP was in favor of MAG (0% vs. 3.1%; p = 0.018, and 1.5% vs. 8.1%; p = 0.003), led by the presence of infarction and stent-thrombosis at 30 days in patients who received ABS. 

At 30 days, target-lesion failure was also lower in MAG. At 12 months MAGMARIS presented lower target-lesion failure, led by lower presence of stent-thrombosis and infarction.

Conclusion

Data from the present study show greater safety and a more favorable clinical evolution of the MAGMARIS Magnesium bioresorbable stent compared with the Absorb polymer stent.

Dr. Carlos Fava - Consejo Editorial SOLACI

Dr. Carlos Fava.
Member of the Editorial Board of SOLACI.org.

Original Title: Outcomes of the two generations of bioresorbable scaffolds (Magmaris vs. Absorb) in acute coronary syndrome in routine clinical practice.

Reference: Piotr Rola, et al. Cardiology Journal, ON LINE FIRST DOI: 10.5603/CJ.a2022.0047. 


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 – ECLIPSE: Randomized Study of Orbital Atherectomy vs Conventional PCI in Severely Calcified Lesions

Coronary calcification is associated with stent under-expansion and increased risk of both early and late adverse events. Atherectomy is an essential tool for uncrossable...

TCT 2024 | Use of Drug-Coated Balloons for Side Branch Treatment in Provisional Stenting

In some cases, treating coronary bifurcations with provisional stenting requires side branch stenting, which may lead to suboptimal outcomes. Drug-coated balloons (DCBs) have emerged...

TCT 2024 | Use of Artificial Intelligence for Patients with Suspected Coronary Artery Disease

The current approach to chest pain mainly focuses on symptom characteristics, conducting functional tests for ischemia assessment. However, several randomized clinical trials have shown...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...